---
title: "polarix"
slug: "polarix"
date: "2024-05-07"
enableToc: false
tags:
  - building
---

> [!info]
>
> ğŸŒ± ä¾†è‡ªï¼š[[double_hit_and_double_expressors_in_lymphoma]]

# polarix

> Tilly H, Morschhauser F, Sehn LH, et al. Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. The New England journal of medicine. 2022;386(4):351-363. doi:10.1056/NEJMoa2115304

1. - **Design**: Phase 3, double-blind, placebo-controlled, international trial
2. - **Number of patients**: 879 patients
3. - **Patients characteristics**: Patients with previously untreated intermediate-risk or high-risk DLBCL, aged 18 to 80 years
4. - **Agent**:
   - Intervention group: Polatuzumab vedotin in place of vincristine in R-CHOP
   - Control group: Standard R-CHOP
5. - **Treatment line**: Previously untreated
6. - **Trial Acronym (NCTId Number)**: NCT03274492
7. - **Comparison of outcomes**:

| Outcome                   | Pola-R-CHP Group             | R-CHOP Group                 |
| ------------------------- | ---------------------------- | ---------------------------- |
| Progression-free survival | 76.7% (95% CI, 72.7 to 80.8) | 70.2% (95% CI, 65.8 to 74.6) |
| Overall survival          | 88.7% (95% CI, 85.7 to 91.6) | 88.6% (95% CI, 85.6 to 91.6) |
| Response rate             | not reported                 | not reported                 |

: çœ‹èµ·ä¾†æ˜¯ OS å¥½åƒæ²’ä»€éº¼å·®ğŸ˜‚
